← Back to patent-cliff list
Cleminorexton
Tier C — Watch / tradeCleminorexton
Centessa Pharmaceuticals Plc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：OX2R
Indications (approved)：发作性睡病, 特发性嗜睡症
Regional status
US
Phase III
2026-05-29
EU
Phase II
2024-12-23
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cleminorexton?
Approved indications include: 发作性睡病, 特发性嗜睡症.
When does the Cleminorexton patent expire?
No public expiry year is available for Cleminorexton yet; this page updates once verified.
How do I get a quote for Cleminorexton intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29